227757
碳负载钯催化剂
sulfided, extent of labeling: 5 wt. % loading (dry basis), matrix activated carbon, wet support, (wet)
别名:
Pd/C
质量水平
表单
(wet)
包含
≤50% water
反应适用性
core: palladium
reaction type: Buchwald-Hartwig Cross Coupling Reaction
reaction type: Heck Reaction
reaction type: Hiyama Coupling
reaction type: Negishi Coupling
reaction type: Sonogashira Coupling
reaction type: Stille Coupling
reaction type: Suzuki-Miyaura Coupling
reagent type: catalyst
标记范围
5 wt. % loading (dry basis)
重量
Unit weight excludes weight of water
基质
activated carbon, wet support
SMILES字符串
[Pd]
InChI
1S/Pd
InChI key
KDLHZDBZIXYQEI-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
相关类别
应用
催化以下反应：
- Stille反应
- 氢化反应
- Suzuki-Miyaura交叉偶联反应和Heck-Mizoroki反应
- 脱氧反应
- 氧化反应
- 偶联反应
警示用语：
Danger
危险声明
危险分类
Flam. Sol. 1
储存分类代码
4.1B - Flammable solid hazardous materials
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Carmen Abate et al.
Journal of medicinal chemistry, 57(8), 3314-3323 (2014-04-05)
Despite the promising potentials of σ2 receptors in cancer therapy and diagnosis, there are still ambiguities related to the nature and physiological role of the σ2 protein. With the aim of providing potent and reliable tools to be used in
Carmen Abate et al.
ChemMedChem, 6(1), 73-80 (2010-11-12)
Many new chemotherapeutic agents are under preclinical investigation and, despite efforts to more selectively target cancer cells, limitations such as toxicity and inherent resistance are often encountered. Therefore, alternative strategies are needed to treat cancer and overcome such limitations. We
Carmen Abate et al.
ChemMedChem, 7(10), 1847-1857 (2012-08-15)
σ(2) Receptor research is receiving increasing interest with regard to the potential of σ(2) proteins as targets for tumor therapy and diagnosis. Nevertheless, knowledge about the σ(2) receptor is far from conclusive. The paucity and modest affinity of known σ(2)
Maria Laura Pati et al.
Pharmacological research, 117, 67-74 (2016-12-23)
A controversial relationship between sigma-2 and progesterone receptor membrane component 1 (PGRMC1) proteins, both representing promising targets for the therapy and diagnosis of tumors, exists since 2011, when the sigma-2 receptor was reported to be identical to PGRMC1. Because a
Francesco Berardi et al.
Journal of medicinal chemistry, 52(23), 7817-7828 (2009-10-22)
sigma(2)-Agonist 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (7, PB 28), which proved to revert doxorubicin resistance in breast cancer cells, was taken as a template to prepare new analogs. One of the two basic N-atoms was alternatively replaced by a methine or converted into an
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持